Skip to content

Clinical study of parathyroid hormone in preventing re-fracture after osteoporosis

Clinical study of parathyroid hormone in preventing re-fracture after osteoporosis

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016971
Enrollment
Unknown
Registered
2018-07-05
Start date
2018-07-05
Completion date
Unknown
Last updated
2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic vertebral fracture

Interventions

Conventional treatment group:calcium tablets 600mg and active vitamin D 0.25ug
PTH group:20 mg of subcutaneous injection of PTH was administered once a day for 6 months on the basis of routine treatment group

Sponsors

Shenzhen Nanshan District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patient informed consent. Inform the breast cancer about the possible danger. Age between 55-85. Osteoporotic Vertebroplasty within 1 month after surgery.

Exclusion criteria

Exclusion criteria: secondary osteoporosis. There are various medical history or manifestations of malignant diseases. Severe chronic diseases, such as abnormal liver and kidney function. Endocrine diseases, such as diabetes, thyroid disease, parathyroid disease, adrenal disease, osteomalacia. Long-term use of anti-epileptic drugs, adrenocorticotropic hormone, diuretics and heparin.Estrogen and calcitonin have been used in the past six months. VitD (more than 1000 iu/d) has been supplemented above physiological requirements.Taking bisphosphonates or sodium fluoride in the past year. In the past three months, traditional Chinese medicine and other unregistered foods were regularly taken to enhance physical fitness. Have one of the following histories or diseases: thrombophlebitis, thrombosis or thromboembolism associated with the use of estrogen, cerebrovascular accidents, known or suspected estrogen-dependent tumors, undiagnosed vaginal bleeding, and cervix The smear graded at grade III or above, severe uterine disorders, severe breast disease, severe gallbladder disease, severe hypertension, and hypercholesterolemia.

Design outcomes

Primary

MeasureTime frame
Re-fracture rate;

Secondary

MeasureTime frame
Bone metabolism index;

Countries

China

Contacts

Public ContactYang Dazhi

Shenzhen Nanshan District People's Hospital

dazhiyang@yeah.net+86 13670064780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026